Bendamustine rituximab (BR) versus ibrutinib (Ibr) as primary therapy for Waldenström macroglobulinemia (WM): An international collaborative study.
Year: 2022
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jithma P. Abeykoon, Shaji Kumar, Jorge J. Castillo, Shirley D'Sa, Efstathios Kastritis, Eric Durot, Encarl Uppal, Pierre Morel, Jonas Paludo, Reema Tawfiq, Shayna Sarosiek, M Olabisi Ogunbiyi, Pascale Cornillet-Lefebvre, Robert A. Kyle, Alain Delmer, Morie A. Gertz, Meletios A. Dimopoulos, Steven P. Treon, Stephen M. Ansell, Prashant Kapoor
Institutions: Mayo Clinic, Harvard University, Dana-Farber Cancer Institute, University College London Hospitals NHS Foundation Trust, University College London, National and Kapodistrian University of Athens, Centre Hospitalier Universitaire de Reims, Centre Hospitalier de Lens, Boston University, Boston Medical Center, Hôpital Robert-Debré
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4281945596